209 related articles for article (PubMed ID: 29447919)
1. Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer.
Ye Q; Wang C; Xian J; Zhang M; Cao Y; Cao Y
Hum Pathol; 2018 May; 75():81-90. PubMed ID: 29447919
[TBL] [Abstract][Full Text] [Related]
2. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
[TBL] [Abstract][Full Text] [Related]
3. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients.
Jia Y; Wang H; Wang Y; Wang T; Wang M; Ma M; Duan Y; Meng X; Liu L
Int J Cancer; 2015 Sep; 137(5):1095-106. PubMed ID: 25683635
[TBL] [Abstract][Full Text] [Related]
4. High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer.
Wei L; Zhu S; Li M; Li F; Wei F; Liu J; Ren X
Front Immunol; 2018; 9():724. PubMed ID: 29719533
[TBL] [Abstract][Full Text] [Related]
5. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.
Sharma MD; Baban B; Chandler P; Hou DY; Singh N; Yagita H; Azuma M; Blazar BR; Mellor AL; Munn DH
J Clin Invest; 2007 Sep; 117(9):2570-82. PubMed ID: 17710230
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma.
Tierney JF; Vogle A; Finnerty B; Zarnegar R; Ghai R; Gattuso P; Fahey TJ; Keutgen XM
J Surg Res; 2020 Dec; 256():90-95. PubMed ID: 32683062
[TBL] [Abstract][Full Text] [Related]
7. Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.
Gide TN; Allanson BM; Menzies AM; Ferguson PM; Madore J; Saw RPM; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Histopathology; 2019 May; 74(6):817-828. PubMed ID: 30589949
[TBL] [Abstract][Full Text] [Related]
8. [Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer].
Sakurai K; Amano S; Enomoto K; Kashio M; Saito Y; Sakamoto A; Matsuo S; Suzuki M; Kitajima A; Hirano T; Negishi N
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1546-9. PubMed ID: 16315864
[TBL] [Abstract][Full Text] [Related]
9. Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
Hacking S; Chavarria H; Jin C; Perry A; Nasim M
Pathol Res Pract; 2020 Apr; 216(4):152847. PubMed ID: 32085927
[TBL] [Abstract][Full Text] [Related]
10. [Expression of indoleamine 2, 3-dioxygenase and its correlation with prognosis in breast cancer patients].
Liu JT; Wei LJ; Yu JP; Li H; Li RM; Zang FL; Sun JY; Ren XB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):513-6. PubMed ID: 22093628
[TBL] [Abstract][Full Text] [Related]
11. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Volaric A; Gentzler R; Hall R; Mehaffey JH; Stelow EB; Bullock TN; Martin LW; Mills AM
Am J Surg Pathol; 2018 Sep; 42(9):1216-1223. PubMed ID: 29901571
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer.
Mansfield AS; Heikkila PS; Vaara AT; von Smitten KA; Vakkila JM; Leidenius MH
BMC Cancer; 2009 Jul; 9():231. PubMed ID: 19604349
[TBL] [Abstract][Full Text] [Related]
14. Analysis of indoleamine 2-3 dioxygenase (IDO) and EGFR co-expression in breast cancer tissue by immunohistochemistry.
Bi WW; Zhang WH; Yin GH; Luo H; Wang SQ; Wang H; Li C; Yan WQ; Nie DZ
Asian Pac J Cancer Prev; 2014; 15(14):5535-8. PubMed ID: 25081660
[TBL] [Abstract][Full Text] [Related]
15. Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma.
Yang C; Zhou Y; Zhang L; Jin C; Li M; Ye L
Int J Clin Exp Pathol; 2015; 8(2):1768-75. PubMed ID: 25973066
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.
Takamatsu M; Hirata A; Ohtaki H; Hoshi M; Ando T; Ito H; Hatano Y; Tomita H; Kuno T; Saito K; Seishima M; Hara A
Cancer Sci; 2015 Aug; 106(8):1008-15. PubMed ID: 26033215
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model.
Källberg E; Wikström P; Bergh A; Ivars F; Leanderson T
Prostate; 2010 Sep; 70(13):1461-70. PubMed ID: 20687219
[TBL] [Abstract][Full Text] [Related]
18. Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.
Zhao Y; Wei L; Liu J; Li F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):77-93. PubMed ID: 31844921
[TBL] [Abstract][Full Text] [Related]
19. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
Dill EA; Dillon PM; Bullock TN; Mills AM
Mod Pathol; 2018 Oct; 31(10):1513-1522. PubMed ID: 29802358
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival.
Alessi C; Scapulatempo Neto C; Viana CR; Vazquez VL
Melanoma Res; 2017 Dec; 27(6):565-572. PubMed ID: 28984690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
